Investigating a new treatment pathway for Type 1 Diabetes
Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes
This study is looking at a special antibody that might help people with Type 1 Diabetes by boosting certain immune cells to protect the insulin-producing cells in the pancreas, with hopes of creating a new treatment that works better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10915582 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific antibody targeting the TLR4 signaling pathway can reverse Type 1 Diabetes (T1D) by activating immune cells that suppress the autoimmune response. The study will explore the mechanisms behind this antibody's effectiveness, particularly how it mobilizes myeloid-derived suppressor cells to protect insulin-producing cells in the pancreas. By applying findings from animal models to human T1D, the research aims to develop a novel therapeutic approach that could significantly improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 Diabetes who are experiencing challenges with current treatment options.
Not a fit: Patients with Type 2 Diabetes or those whose diabetes is not autoimmune in nature may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that effectively reverses Type 1 Diabetes in patients.
How similar studies have performed: Previous research has shown promising results with similar immune-targeting approaches in animal models, but this specific application in humans is novel.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Ridgway, William M — University of California at Davis
- Study coordinator: Ridgway, William M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.